World

Portuguese social security surplus shrinks slightly amid rising costs

Aug 31, 2024

Lisbon [Portugal], August 31: Portugal's Social Security system recorded a surplus of 2,712.4 million euros by the end of July 2024, slightly down from 2,756.0 million euros in the same period last year, according to figures released on Friday by Portugal's Directorate-General for the Budget.
This decrease occurred as Social Security spending increased by 12.4 percent to 20,698.3 million euros, outpacing a 10.5-percent rise in revenue, which reached 23,410.7 million euros.
Pensions contributed significantly to the higher expenses, rising by 13.0 percent to 12,924.8 million euros, with old-age pensions seeing a 14.1-percent increase. Meanwhile, unemployment benefits grew by 19.0 percent, totaling 928.6 million euros by July.
Additionally, the inflationary and energy crisis impacted the state's finances, costing 1,651.8 million euros by July. This included a revenue decrease of 722.8 million euros and an expenditure increase of 929 million euros, largely due to tax adjustments and energy support measures.
Despite these challenges, state tax revenue grew by 7.6 percent, totaling 33,403.7 million euros, driven by increases in Corporate Income Tax and the Tax on Petroleum Products. (1 euro = 1.105 U.S. dollars)
Source: Xinhua

More news

Concept Medical Announces Successful SIRONA Trial Results, Demonstrating Sirolimus-Coated Balloon as a Promising Alternative for PAD Treatment

Tampa (Florida) [US], January 7: Concept Medical Inc., a global leader in innovative drug-delivery technology, proudly reports positive outcomes from the SIRONA (Head-to-Head Comparison of SIROlimus versus Paclitaxel Drug-Eluting BallooNAngioplasty in the Femoropopliteal Artery) RCT, which show that its sirolimus-coated balloons (SCB) (MagicTouch -PTA) provide patency and functional benefits on par with paclitaxel-coated balloons for patients suffering from peripheral artery disease (PAD). The 1-year data was presented by Principal Investigator Prof. Ulf Teichgraber at the TCT USA 2024 conference in a Late-Breaking Clinical Trials Session (LBCT). Coverage by TCTMD has highlighted these findings, underscoring sirolimus-based therapy as a viable new option in femoropopliteal interventions.

Jan 07, 2025